Quantum-Si (NASDAQ:QSI) CEO Jeffrey Alan Hawkins Sells 11,310 Shares

Quantum-Si Incorporated (NASDAQ:QSI) CEO Jeffrey Alan Hawkins sold 11,310 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $0.96, for a total value of $10,857.60. Following the completion of the sale, the chief executive officer directly owned 3,681,113 shares of the company’s stock, valued at $3,533,868.48. This represents a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jeffrey Alan Hawkins also recently made the following trade(s):

• On Tuesday, June 23rd, Jeffrey Alan Hawkins sold 11,311 shares of Quantum-Si stock. The stock was sold at an average price of $0.90, for a total transaction of $10,179.90.
• On Monday, April 20th, Jeffrey Alan Hawkins sold 83,712 shares of Quantum-Si stock. The shares were sold at an average price of $1.01, for a total value of $84,549.12.

Quantum-Si Stock Down 6.0%

NASDAQ:QSI traded down $0.05 during mid-day trading on Wednesday, hitting $0.83. 5,042,480 shares of the stock traded hands, compared to its average volume of 6,078,957. The business’s 50-day moving average price is $0.99 and its 200 day moving average price is $1.04. The company has a market cap of $180.13 million, a PE ratio of -1.62 and a beta of 3.18. Quantum-Si Incorporated has a 12-month low of $0.69 and a 12-month high of $3.10.

Quantum-Si (NASDAQ:QSI) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02. Quantum-Si had a negative return on equity of 47.35% and a negative net margin of 5,605.88%.The company had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.30 million. Analysts anticipate that Quantum-Si Incorporated will post -0.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Quantum-Si in a report on Friday, March 27th. Canaccord Genuity Group dropped their target price on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a research report on Wednesday, March 4th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $1.00.

Hedge Funds Weigh In On Quantum-Si

A number of hedge funds and other institutional investors have recently modified their holdings of QSI. Prudential Financial Inc. bought a new position in shares of Quantum-Si during the 2nd quarter valued at about $25,000. Curbstone Financial Management Corp bought a new stake in Quantum-Si in the 4th quarter worth approximately $26,000. Leonteq Securities AG purchased a new stake in Quantum-Si in the fourth quarter worth approximately $28,000. Cerity Partners LLC purchased a new stake in Quantum-Si in the second quarter worth approximately $29,000. Finally, Hollencrest Capital Management grew its position in Quantum-Si by 301.1% during the first quarter. Hollencrest Capital Management now owns 40,111 shares of the company’s stock valued at $31,000 after acquiring an additional 30,111 shares during the last quarter. 39.90% of the stock is currently owned by hedge funds and other institutional investors.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.